A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus

NCT07630714 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
24
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

AstraZeneca